19 completed, 3 active not recruiting, 1 not yet recruiting, 1 unknown. 7 Phase 1, 6 Phase 3, 2 Phase 2, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Active not recruiting 1 |
| Phase 3 | 6 | Completed 4, Active not recruiting 2 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
Follow Female Contraception: new trials by email Literature Review of Female Contraception trials Research Report on Female Contraception
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception Levonorgestrel butanoate - Healthy Women, Female Contraception | Phase 2 | Not yet recruiting | Premier Research | 165 | 2026-04-01 | 2025-10-29 |
| Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive Mifepristone 50 mg - Female Contraception | Phase 3 | Active not recruiting | Leiden University Medical Center | 615 | 2025-05-02 | 2026-06-08 |
| Patient Factors Associated With Fragmentation of Copper Intrauterine Device (IUD) Requiring Hysteroscopic Removal Intrauterine Device Complications, Contraceptive Device Failure | Completed | University of Kansas Medical Center | 44 | 2025-02-28 | 2026-06-30 | |
| Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential Transdermal system containing progestin - Female Contraception | Phase 3 | Active not recruiting | Mylan Pharmaceuticals Inc | 1630 | 2025-01-13 | 2026-10-13 |
| A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception levonorgestrel butanoate (LB) injection - Healthy Women, Female Contraception | Phase 1 | Active not recruiting | Premier Research | 136 | 2020-03-03 | 2025-10-29 |
| Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring NES-E2 CVR - Healthy Women, Female Contraception | Phase 2 | Completed | Premier Research | 385 | 2018-02-12 | 2025-10-31 |
| Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard Mona Lisa® NT Cu380 Mini, ParaGard® TCu380A - Healthy Women, Female Contraception | Phase 3 | Completed | FHI 360 | 1105 | 2017-05-26 | 2024-09-25 |
| Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice Levonorgestrel IUD (Mirena, BAY86-5028) - Female Contraception | Completed | Bayer | 35 | 2013-02-01 | 2015-09-14 | |
| Oral Contraceptives and Economic Behaviour Oral contraceptive - Female Contraception | Not applicable | Unknown | Karolinska University Hospital | 400 | 2012-02-01 | 2014-10-06 |
| Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B) - Female Contraception | Phase 1 | Completed | Population Council | 20 | 2011-01-01 | 2017-08-15 |
| A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy DR-102 - Contraception, Female Contraception | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 2858 | 2010-08-01 | 2021-11-09 |
| Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives. Contraception, Female Contraception | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 440 | 2006-11-01 | 2016-07-19 | |
| Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women. Norgestimate/Ehinyl Estradiol; Folic acid. - Female Contraception, Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 53 | 2005-05-01 | 2011-06-08 |
| Bioequivalence Study of Patches With Different Equilibration Profiles norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system. - Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 42 | 2004-05-01 | 2011-06-08 |
| A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive) EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 60 | 2004-05-01 | 2011-06-08 |
| A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch) EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE - Contraception, Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 53 | 2004-04-01 | 2012-12-12 |
| Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception. norelgestromin + ethinyl estradiol - Contraception, Female Contraception | Phase 4 | Completed | Janssen Pharmaceutica N.V., Belgium | 778 | 2003-07-01 | 2010-11-16 |
| Bioequivalence Study of Patches With Different Release Profiles Female Contraception | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 43 | 2003-03-01 | 2011-06-08 | |
| An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method norelgestromin; ethinyl estradiol - Female Contraception | Phase 4 | Completed | Janssen-Ortho Inc., Canada | 405 | 2002-10-01 | 2010-03-26 |
| A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 34 | 2002-08-01 | 2011-06-08 |
Showing 20 of 24. Sign in to see all of them.
Venous Thromboembolism (2) · Amenorrhea (1) · Thrombosis (1)
Cardiovascular Diseases (2) · Embolism and Thrombosis (2) · Thromboembolism (2) · Vascular Diseases (2) · Menstruation Disturbances (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Ethinyl Estradiol (8) · norelgestromin (7) · Levonorgestrel (3) · levonorgestrel butanoate (2) · Contraceptives, Oral (1) · Ethinyl Estradiol-Norgestrel Combination (1) · Folic Acid (1) · Gels (1) · Mifepristone (1) · norgestimate (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (11) · Premier Research (3) · Bayer (1) · FHI 360 (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Ortho Inc., Canada (1) · Karolinska University Hospital (1) · Leiden University Medical Center (1) · Mylan Pharmaceuticals Inc (1) · Population Council (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · University of Kansas Medical Center (1)
United States (6) · Algeria (1) · Chile (1) · Dominican Republic (1) · Israel (1) · Netherlands (1) · Sweden (1)
Diana Blithe (2) · Angelica L Hirschberg, Professor (1) · Annabel Mancillas, MD MPH FACOG (1) · David Hubacher (1) · Diana Blithe, PhD (1) · Rebecca Gomperts, PhD (1) · Regine Sitruk-Ware, PhD. (1) · Vivian Brache, Lic. (1)
PMID 11849631, PMID 11849634, PMID 11704172, PMID 15937609, PMID 16472560, PMID 17267834, PMID 35865736, PMID 40693846